Diabetes Care Global Market Report 2025

The rising prevalence of obesity is anticipated to drive the expansion of the diabetes care market in the coming years. Obesity rates refer to the proportion of individuals within a population who have a body mass index (BMI) of 30 or above, indicating obesity. The growth in obesity is largely due to increased dependence on sedentary lifestyles and the widespread consumption of highly processed, calorie-dense foods that offer minimal nutritional value, leading to an imbalance between caloric intake and physical activity. Diabetes care is essential in addressing obesity-related health challenges by promoting better lifestyle habits, enhancing glucose regulation, and supporting weight management through advanced treatment options like insulin therapy and continuous glucose monitoring (CGM) technologies. For instance, in March 2024, the World Health Organization, an intergovernmental body based in Switzerland, reported that in 2.02 trillion adults were underweight, while 2.5 billion were overweight, including 890 million classified as obese. As a result, increasing obesity levels are fueling demand within the diabetes care market.

Leading companies in the diabetes care industry are innovating with new technologies, such as automated insulin delivery (AID) systems, to enhance glucose control by seamlessly integrating continuous glucose monitoring devices with insulin pumps for real-time insulin adjustments. AID systems combine CGMs with insulin pumps to automatically manage insulin levels based on current glucose readings, helping patients maintain more consistent blood sugar control. For example, in February 2024, Tandem Diabetes Care Inc., a U.S.-based medical device company focused on diabetes treatment, launched the Tandem Mobi - an ultra-compact, durable automated insulin delivery system. This discreet, tubed insulin pump can be fully operated via a smartphone app, eliminating the need for a traditional controller. The device is waterproof, rechargeable, and integrates with Dexcom’s CGM system, utilizing Tandem’s established Control-IQ technology to automate insulin dosing.

In January 2023, Tandem Diabetes Care Inc. acquired AMF Medical SA for an undisclosed amount. This acquisition is aimed at accelerating the development and commercialization of advanced patch pump technology, broadening Tandem’s diabetes care offerings, and reaching a wider patient base. AMF Medical SA is a Switzerland-based company specializing in innovative insulin delivery solutions for diabetes management.

Major players in the diabetes care market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Medtronic plc, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim Pharmaceuticals Inc., Terumo Corporation, Dexcom Inc., Dr. Reddy's Laboratories Limited, SD Biosensor Inc., Insulet Corporation, Tandem Diabetes Care Inc., LifeScan Inc., Ypsomed AG, Ascensia Diabetes Care Holdings AG, B. Braun Melsungen AG, Bionime Corporation, Arkray Inc., ACON Laboratories Inc., ViCentra B.V., Microtech Medical Ltd., Sinocare Inc., MicroGene Diagnostic Systems Pvt. Ltd.

North America was the largest region in the diabetes care market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetes care report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetes care market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetes care market consists of revenues earned by entities by providing services such as insulin therapy and medication management, nutrition and diet planning, lifestyle modification support, and telemedicine and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes care market also consists of sales of products including dietary and nutritional products, medication delivery devices, and digital and software solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.